Acadia Healthcare Company, Inc.

Valuation Analysis

About the Company

Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company owns and operates acute inpatient psychiatric facilities; specialty treatment facilities comprising residential recovery facilities and eating disorder facilities; comprehensive treatment centers; and residential treatment centers, as well as facilities providing outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.

Acadia Healthcare Company, Inc. Stock at a Glance

Acadia Healthcare Company, Inc. (ACHC) is currently trading at $24.60 with a market capitalization of $2.3B. The 52-week range spans from $11.43 to $30.20; the current price is 18.5% below the yearly high. Year-over-year revenue growth stands at +7.6%.

💰 Dividend

Acadia Healthcare Company, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

14 analysts rate Acadia Healthcare Company, Inc. (ACHC) on consensus: Buy. The average price target is $28.86, implying +17.31% from the current price. Analyst price targets range from $13.00 to $39.00.

Acadia Healthcare Company, Inc.: The Investment Case in Detail

Acadia Healthcare Company, Inc. (ACHC) operates in the Healthcare — specifically Medical Care Facilities — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Wall Street consensus sits at Buy with an average price target implying roughly 17.31% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 38.6% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

The PEG ratio at 1.37 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric. The EV/EBITDA multiple of 8.52x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (38.6%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Acadia Healthcare Company, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.